MRMaría José Ramírez-Lázaro

María José Ramírez-Lázaro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


María José Ramírez-Lázaro has a total of 66 co-authors. Here are the top co-authors by number of shared publications:

  • Sergio Lario

    Servei d’Aparell Digestiu, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí (I3PT-CERCA), Departament de Medicina, Universitat Autònoma de Barcelona, 08208 Sabadell, Spain

    9 shared publications
  • Xavier Calvet

    Gastroenterology Department, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Parc Taulí Hospital Universitari, Sabadell, Spain

    8 shared publications
  • María Elisa Quílez

    Oncology Service, Hospital de Sabadell, Corporació Sanitària Parc Taulí, Institut Universitari Parc Taulí-UAB, Sabadell, Spain

    5 shared publications
  • Anna Brunet-Vega

    Oncology Service, Hospital de Sabadell, Corporació Sanitària Parc Taulí, Institut Universitari Parc Taulí-UAB, Sabadell, Spain

    4 shared publications
  • Antònia Montserrat

    Servei Aparell Digestiu, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí, Sabadell, Spain

    4 shared publications
  • Carles Pericay

    Department of Medical Oncology, Hospital Universitari Mútua de Terrassa, Terrassa, Spain

    3 shared publications

Latest Publications

  • Application of Individual qPCR Performance Parameters for Quality Control of Circulating MicroRNA Data

    by Anna Brunet-Vega, María Elisa Quílez, María José Ramírez-Lázaro, Sergio Lario

    Although circulating miRNAs are promising candidates for biomarkers, several challenges must be overcome before miRNAs can be used for diagnosis and monitoring. One is quality control for the RNA extraction and quantification process. RNA quality control techniques are unsuitable as circulating miRNAs are in the fM range. Additionally, biofluids may contain inhibitors of the reverse transcriptase and polymerase enzymes, which may survive RNA purification. Herein, we describe the protocol we have used to check the robustness of miRNA purification and measurement by the addition of spike-ins and by evaluating the quality of the qPCR data, respectively.


  • Open Access

    Fatigue in out-patients with inflammatory bowel disease: Prevalence and predictive factors

    by Albert Villoria, Víctor García, Angelina Dosal, Laura Moreno, Antònia Montserrat, Ariadna Figuerola, Diana Horta, Xavier Calvet, María José Ramírez-Lázaro

    Fatigue is a common and bothersome symptom in inflammatory bowel disease (IBD) patients. The study was aimed to determine the relationship of biological and psychological factors with IBD-related fatigue. Consecutive clinically inactive IBD outpatients receiving immunosuppressants or biological drugs were enrolled between January and December 2013. Patients completed a Fatigue score (FACIT-F), various psychological, quality of life (IBDQ-9), and IBD activity scores. Biological parameters were assessed, including levels of interleukins (IL-5, IL-8 and IL-12) and micronutrients. We prospectively recruited 202 patients (28% ulcerative colitis and 72% Crohn’s disease) for the study. Fatigue measured by FACIT-F score was prevalent in the studied population (54%, 96/177) and higher than in the general population. In the univariate analysis no relation was found between IL levels or micronutrient deficiencies and fatigue. Fatigue was significantly related to female sex, Crohn’s disease, joint disorders, body mass index (BMI), psychological tests, thiopurine use, and anti-TNF treatment. All these variables were included in the multivariate analysis. Female sex (OR: 4.8), high BMI (OR:1.2) and higher depression rates (OR:1.2) were predictors of increased fatigue. High IBDQ-9 score (OR: 0.82) was significantly related to lower degrees of fatigue. Fatigue was prevalent in quiescent IBD patients with moderate-to-severe disease. It was associated with high levels of depression, low quality of life, and female sex. No association was found with the other biological and psychological factors evaluated.


  • Metabolomic Analysis of Gastric Cancer Progression within the Correa’s Cascade Using Ultraperformance Liquid Chromatography–Mass Spectrometry

    by Julia Kuligowski, Daniel Sanjuan-Herráez, María A. Vázquez-Sánchez, Anna Brunet-Vega, Carles Pericay, María José Ramírez-Lázaro, Sergio Lario, Lourdes Gombau, Félix Junquera, Xavier Calvet, et al.

    Gastric cancer (GC) is among the most common cancers worldwide. Gastric carcinogenesis is a multistep and multifactorial process beginning with chronic gastritis induced by Helicobacter pylori (H. pylori) infection. This process is often described via a sequence of events known as Correas’s cascade, a stepwise progression from nonactive gastritis, chronic active gastritis, precursor lesions of gastric cancer (atrophy, intestinal metaplasia, and dysplasia), and finally adenocarcinoma. Our aim was to identify a plasma metabolic pattern characteristic of GC through disease progression within the Correa’s cascade. This study involved the analysis of plasma samples collected from 143 patients classified in four groups: patients with nonactive gastritis and no H. pylori infection, H. pylori infected patients with chronic active gastritis, infected or noninfected patients with precursor lesions of gastric cancer, and GC. Independent partial least-squares-discriminant binary models of UPLC-ESI(+)-TOFMS metabolic profiles, implemented in a decision-directed acyclic graph, allowed the identification of tryptophan and kynurenine as discriminant metabolites that could be attributed to indoleamine-2,3-dioxygenase upregulation in cancer patients leading to tryptophan depletion and kynurenine metabolites generation. Furthermore, phenylacetylglutamine was also classified as a discriminant metabolite. Our data suggest the use of tryptophan, kynurenine, and phenylacetylglutamine as potential GC biomarkers.


  • Diagnostic accuracy of three monoclonal stool tests in a large series of untreated Helicobacter pylori infected patients

    by Sergio Lario, María José Ramírez-Lázaro, Antònia Montserrat, María Elisa Quílez, Félix Junquera, Eva Martínez-Bauer, Isabel Sanfeliu, Enric Brullet, Rafael Campo, Ferran Segura, et al.


  • Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: results of the Spanish follow‐up multicenter study

    by González, Carlos A., Sanz‐ Anquela, José Miguel, Osmel Companioni, Catalina Bonet, María Berdasco, Consuelo López, Jorge Mendoza, Martín‐ Arranz, et al.

    Background and Aim: In high or moderate risk populations, periodic surveillance of patients at risk of progression from gastric precursor lesions (PL) to gastric cancer (GC) is the most effective strategy for reducing the burden of GC. Incomplete type of intestinal metaplasia (IIM) may be considered as the best candidate, but it is still controversial and more research is needed. To further assess the progression of subtypes of IM as predictors of GC occurrence.Methods: A follow‐up study was carried‐out including 649 patients, diagnosed with PL between 1995–2004 in 9 participating hospitals from Spain, and who repeated the biopsy during 2011–2013. Medical information and habits were collected through a questionnaire. Based on morphology, IM was sub‐classified as complete (small intestinal type, CIM) and incomplete (colonic type, IIM). Analyses were done using Cox (HR) models.Results: At baseline, 24% of patients had atrophic gastritis, 38% CIM, 34% IIM, and 4% dysplasia. Mean follow‐up was 12 years. 24 patients (3.7%) developed a gastric adenocarcinoma during follow‐up. The incidence rate of GC was 2.76 and 5.76 per 1,000 person‐years for those with CIM and IIM, respectively. The HR of progression to CG was 2.75 (95% CI 1.06‐6.26) for those with IIM compared with those with CIM at baseline, after adjusting for sex, age, smoking, family history of GC and use of NSAIDs.Conclusions: IIM is the PL with highest risk to progress to GC. Sub‐typing of IM is a valid procedure for the identification of high risk patients that require more intensive surveillance.


  • Good Diagnostic Accuracy of a Chemiluminescent Immunoassay in Stool Samples for Diagnosis of Helicobacter Pylori Infection in Patients with Dyspepsia

    by María José Ramírez-Lázaro, Josep Lite, Sergio Lario, Pepa Pérez-Jové, Antònia Montserrat, María Elisa Quílez, Eva Martínez-Bauer, Xavier Calvet

    Laboratory-based chemiluminescence immunoassays (CLIA) are widely used in clinical laboratories. Some years ago, a CLIA test was developed for the detection of Helicobacter pylori in stool samples, known as LIAISON H. pylori SA, but little information on its use has been reported. To evaluate the accuracy of the LIAISON H. pylori SA assay for diagnosing H. pylori infection prior to eradication treatment. Diagnostic reliability was evaluated in 252 untreated consecutive patients with dyspepsia. The gold standard for diagnosing H. pylori infection was defined as the concordance of the rapid urease test (RUT), histopathology and urea breath test (UBT). The CLIA assay was performed according to the manufacturer's instructions. Sensitivity, specificity, positive and negative predictive values, and 95% CIs were calculated. According to the gold standard selected, 121 patients were positive for H. pylori infection and 131 negative. LIAISON H. pylori SA had a sensitivity of 90.1% and a specificity of 92.4%, with positive and negative predictive values of 91.6% and 90.1%, respectively. The accuracy of the LIAISON H. pylori SA chemiluminescent diagnostic assay seems comparable to that of ELISA or the best-performing LFIAs. Its sensitivity and specificity, however, seem slightly lower than those of histology, RUT or UBT. The advantages of the assay are that it is cheap, automated, and minimally labor-intensive.


  • Open Access

    Data on individual PCR efficiency values as quality control for circulating miRNAs

    by Anna Brunet-Vega, Carles Pericay, María Elisa Quílez, María José Ramírez-Lázaro, Xavier Calvet, Sergio Lario


  • Variability in microRNA recovery from plasma: Comparison of five commercial kits

    by Anna Brunet-Vega, Carles Pericay, María Elisa Quílez, María José Ramírez-Lázaro, Xavier Calvet, Sergio Lario


  • Open Access

    microRNA profiling in duodenal ulcer disease caused by Helicobacter pylori infection in a Western population

    by S. Lario, M.J. Ramírez-Lázaro, A.M. Aransay, J.J. Lozano, A. Montserrat, Á. Casalots, F. Junquera, J. Álvarez, F. Segura, R. Campo, et al.


  • Open Access

    Real-Time PCR Improves Helicobacter pylori Detection in Patients with Peptic Ulcer Bleeding

    by María José Ramírez-Lázaro, Sergio Lario, Alex Casalots, Esther Sanfeliu, Loreto Boix, Pilar García-Iglesias, Jordi Sánchez-Delgado, Antònia Montserrat, Maria Rosa Bella-Cueto, Marta Gallach, et al.

    Histological and rapid urease tests to detect H. pylori in biopsy specimens obtained during peptic ulcer bleeding episodes (PUB) often produce false-negative results. We aimed to examine whether immunohistochemistry and real-time PCR can improve the sensitivity of these biopsies. We selected 52 histology-negative formalin-fixed paraffin-embedded biopsy specimens obtained during PUB episodes. Additional tests showed 10 were true negatives and 42 were false negatives. We also selected 17 histology-positive biopsy specimens obtained during PUB to use as controls. We performed immunohistochemistry staining and real-time PCR for 16S rRNA, ureA, and 23S rRNA for H. pylori genes on all specimens. All controls were positive for H. pylori on all PCR assays and immunohistochemical staining. Regarding the 52 initially negative biopsies, all PCR tests were significantly more sensitive than immunohistochemical staining (pH. pylori infection in histology-negative formalin-fixed paraffin-embedded biopsy samples obtained during PUB episodes. The low reported prevalence of H. pylori in PUB may be due to the failure of conventional tests to detect infection.